clinical trial · NCT06111014
Continuation Study for Latozinemab
Neurodegenerative DiseasesLatozinemab
brief summary
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
started
Dec 8, 2023
primary completion
Sep 1, 2025
completion
Jan 7, 2026
last updated
Jan 21, 2026
detailed description
This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).
official title
A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol